Want to see PHAT full AI Analyst Report?
Phathom Pharmaceuticals (PHAT) Ratios
Phathom Pharmaceuticals Ratios
PHAT's free cash flow for Q3 2026 was $1.94M. For the 2026 fiscal year, PHAT's free cash flow was increased by $105.00K and operating cash flow was $1.84M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.73 | 4.20 | 10.25 | 6.12 | 9.86 |
| Quick Ratio | 1.69 | 4.16 | 10.22 | 6.12 | 9.86 |
| Cash Ratio | 0.98 | 3.47 | 9.83 | 5.92 | 9.69 |
| Solvency Ratio | -0.32 | -0.53 | -0.41 | -0.82 | -1.22 |
| Operating Cash Flow Ratio | -1.26 | -3.11 | -3.55 | -5.58 | -7.85 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -13.49 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -468.35M | $ -271.76M | $ -89.17M | $ -79.11M | $ 69.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.82 | 1.47 | 0.34 | 0.59 | 0.48 |
| Debt-to-Equity Ratio | -0.48 | -2.19 | -1.91 | -1.30 | 1.27 |
| Debt-to-Capital Ratio | -0.94 | 1.84 | 2.10 | 4.36 | 0.56 |
| Long-Term Debt-to-Capital Ratio | -0.91 | 1.90 | 2.12 | 4.66 | 0.55 |
| Financial Leverage Ratio | -0.59 | -1.49 | -5.69 | -2.20 | 2.63 |
| Debt Service Coverage Ratio | -2.24 | -2.85 | -3.79 | -6.22 | -20.12 |
| Interest Coverage Ratio | -2.35 | -3.85 | -3.99 | -6.32 | -19.90 |
| Debt to Market Cap | 0.17 | 1.08 | 0.29 | 0.22 | 0.12 |
| Interest Debt Per Share | 3.84 | 9.92 | 3.53 | 3.18 | 2.65 |
| Net Debt to EBITDA | -0.54 | -0.99 | 1.52 | 0.34 | 0.67 |
| Profitability Margins | |||||
| Gross Profit Margin | 87.09% | 85.57% | 75.51% | 0.00% | 0.00% |
| EBIT Margin | -87.45% | -474.76% | -23405.28% | 0.00% | 0.00% |
| EBITDA Margin | -87.09% | -473.33% | -23320.97% | 0.00% | 0.00% |
| Operating Profit Margin | -91.36% | -502.18% | -24532.55% | 0.00% | 0.00% |
| Pretax Profit Margin | -126.35% | -605.09% | -29558.94% | 0.00% | 0.00% |
| Net Profit Margin | -126.35% | -605.09% | -29558.94% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -126.35% | -605.09% | -29558.94% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 138.29% | 120.49% | 120.49% | 114.66% | 106.52% |
| Return on Assets (ROA) | -85.37% | -88.37% | -48.71% | -119.97% | -75.96% |
| Return on Equity (ROE) | 50.49% | 131.84% | 277.07% | 264.29% | -199.41% |
| Return on Capital Employed (ROCE) | -125.87% | -94.83% | -44.61% | -124.44% | -79.22% |
| Return on Invested Capital (ROIC) | -125.23% | -88.69% | -44.52% | -123.81% | -79.00% |
| Return on Tangible Assets | -85.37% | -88.37% | -48.71% | -119.97% | -75.96% |
| Earnings Yield | -18.29% | -65.17% | -43.05% | -45.05% | -19.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.24 | 1.42 | 0.42 | 0.00 | 0.00 |
| Payables Turnover | 4.54 | 0.76 | 0.01 | 0.06 | 0.10 |
| Inventory Turnover | 4.10 | 2.49 | 0.14 | 0.00 | 0.00 |
| Fixed Asset Turnover | 47.75 | 26.45 | 0.19 | 0.00 | 0.00 |
| Asset Turnover | 0.68 | 0.15 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.94 | 0.17 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 171.49 | -77.85 | -24024.76 | -5885.33 | -3607.97 |
| Days of Sales Outstanding | 162.85 | 256.30 | 876.11 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 89.12 | 146.86 | 2640.24 | 0.00 | 0.00 |
| Days of Payables Outstanding | 80.48 | 481.01 | 27541.11 | 5885.33 | 3607.97 |
| Operating Cycle | 251.97 | 403.16 | 3516.35 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.29 | -4.22 | -2.68 | -3.75 | -4.01 |
| Free Cash Flow Per Share | -2.29 | -4.22 | -2.71 | -3.77 | -4.02 |
| Dividend Paid and CapEx Coverage Ratio | -728.28 | -1976.07 | -84.20 | -140.76 | -452.61 |
| Capital Expenditure Coverage Ratio | -728.28 | -1976.07 | -84.20 | -140.76 | -452.61 |
| Operating Cash Flow Coverage Ratio | -0.79 | -0.48 | -0.99 | -1.51 | -1.63 |
| Operating Cash Flow to Sales Ratio | -0.95 | -4.83 | -201.73 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.79% | -52.03% | -29.73% | -33.62% | -20.44% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.48 | -1.53 | -2.32 | -2.22 | -5.06 |
| Price-to-Sales (P/S) Ratio | 6.91 | 9.28 | 686.61 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -2.76 | -2.02 | -6.44 | -5.87 | 10.09 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.25 | -1.92 | -3.36 | -2.97 | -4.89 |
| Price-to-Operating Cash Flow Ratio | -7.25 | -1.92 | -3.40 | -3.00 | -4.90 |
| Price-to-Earnings Growth (PEG) Ratio | 0.13 | -0.04 | 0.07 | -0.05 | 20.29 |
| Enterprise Value Multiple | -8.47 | -2.95 | -1.42 | -2.24 | -4.66 |
| Enterprise Value | 1.29B | 770.67M | 225.91M | 380.59M | 635.93M |
| EV to EBITDA | -8.47 | -2.95 | -1.42 | -2.24 | -4.66 |
| EV to Sales | 7.38 | 13.95 | 331.24 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.74 | -2.89 | -1.62 | -2.58 | -4.27 |
| EV to Operating Cash Flow | -7.74 | -2.89 | -1.64 | -2.60 | -4.28 |
| Tangible Book Value Per Share | -6.01 | -4.01 | -1.42 | -1.91 | 1.95 |
| Shareholders’ Equity Per Share | -6.01 | -4.01 | -1.42 | -1.91 | 1.95 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.40 | 0.87 | 0.01 | 0.00 | 0.00 |
| Net Income Per Share | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.44 | 1.27 | 1.26 | 1.16 | 1.05 |
| Research & Development to Revenue | 0.19 | 0.62 | 73.17 | 0.00 | 0.00 |
| SG&A to Revenue | 1.60 | 5.26 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.16 | 0.44 | 66.02 | 0.00 | 0.00 |
| Income Quality | 0.75 | 0.80 | 0.68 | 0.74 | 1.03 |
Currency in USD